Get the Stockscreener App
5.30
0.00%
0.00
Trisalus Life Sciences Inc stock is traded at $5.30, with a volume of 17,845.
It is up +0.00% in the last 24 hours and down -4.16% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$5.30
Open:
$5.29
24h Volume:
17,845
Relative Volume:
0.49
Market Cap:
$161.61M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-3.0248
EPS:
-1.7522
Net Cash Flow:
-
1W Performance:
-6.36%
1M Performance:
-4.16%
6M Performance:
+17.26%
1Y Performance:
-43.07%
1-Day Range:
$5.20
$5.30
1-Week Range:
$4.60
$5.68
52-Week Range:
$3.50
$10.42
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.30 | 161.61M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
Can This Revolutionary Liver Cancer Treatment Double Drug Effectiveness? New Study Shows Remarkable Results - StockTitan
Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Expands By 75.3% - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Buy” from Analysts - Defense World
TriSalus Life Sciences announces executive departure By Investing.com - Investing.com South Africa
TriSalus Life Sciences announces executive departure - Investing.com India
3 Stocks With Robust Growth Outlooks Insiders Are Buying - MSN
Trisalus Life Sciences CFO buys $33,900 in common stock - MSN
Dated alert on Trisalus Life Sciences entering credit agreement withdrawn -February 19, 2025 at 08:04 am EST - Marketscreener.com
TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Lake Street Capital - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated at Lake Street Capital - Defense World
Lake Street Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy Recommendation - Nasdaq
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Buys $33,900.00 in Stock - MarketBeat
Financial Comparison: TriSalus Life Sciences (NASDAQ:TLSI) versus Tenon Medical (NASDAQ:TNON) - Defense World
Tenon Medical (NASDAQ:TNON) vs. TriSalus Life Sciences (NASDAQ:TLSI) Head to Head Survey - Armenian Reporter
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young Purchases 6,000 Shares - Armenian Reporter
CFO Makes Bold Move with Major Stock Purchase in TriSalus Life Sciences! - TipRanks
Trisalus Life Sciences CFO buys $33,900 in common stock By Investing.com - Investing.com Canada
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $11.79 - Defense World
TriSalus Life Sciences bolsters board with two new members - MSN
Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Purchases $25,300.90 in Stock - MarketBeat
TriSalus Life Sciences announces drawdown of $10M under credit agreement with OrbiMed - MSN
Trisalus Life Sciences Announces Key Appointments To Board Of Directors -February 03, 2025 at 05:03 pm EST - Marketscreener.com
TriSalus Life Sciences bolsters board with two new members By Investing.com - Investing.com South Africa
Healthcare Powerhouses Join TriSalus Board: Ex-Fresenius CEO and AbbVie Oncology Pioneer Unite - StockTitan
TriSalus Life Sciences, Inc. Announces Drawdown of $10 Million Tranche Under Credit Agreement with Orbimed - Marketscreener.com
Revenue Success: TriSalus Unlocks $10M Strategic Funding from Healthcare Giant OrbiMed - StockTitan
Trisalus life sciences director Sean Murphy buys $157,200 in stock - MSN
TriSalus Life Sciences expands board, appoints new directors By Investing.com - Investing.com Nigeria
TriSalus Life Sciences expands board, appoints new directors - MSN
Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases 24,000 Shares of Stock - MarketBeat
Mary T. Szela Purchases 4,826 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Sean Murphy Buys 15,000 Shares - MarketBeat
Trisalus life sciences CFO buys shares worth $129,600 - MSN
Trisalus life sciences CEO buys $50,302 in stock - MSN
Trisalus life sciences CEO buys $50,302 in stock By Investing.com - Investing.com Australia
TriSalus Life Sciences (NASDAQ:TLSIW) Trading Down 2.9% – What’s Next? - Defense World
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):